As cell therapy advances toward clinical reality, iPSC-derived cellular products, in vivo reprogramming strategies, and ...

An innovative stem cell therapy approved for severe heart failure has been cleared for use in Japan. Here is why it matters ...

A Kyoto-based regenerative medicine company is launching a service that will allow individuals to generate and store induced ...

Sumitomo Pharma America, Inc. (SMPA) today announced that the U.S. Food and Drug Administration (FDA) granted Orphan Drug designation to its investigational therapy DSP-3077 for the treatment of ...

A Kyoto-based regenerative medicine company is launching a service that will allow individuals to generate and store induced ...

A third "just in case" service to proactively store induced pluripotent stem (iPS) cells created with a client's blood for ...

A pharmaceutical startup plans to begin a clinical trial in 2027 on a treatment for spinal cord injuries that uses nerve ...

Aspen Neuroscience’s autologous, personalised stem cell therapy is set for a pivotal trial after it showed improved "ON" and ...

Intermediate-scale benchtop bioreactor protocol streamlines production of iPSC-derived macrophages for research, drug discovery, and modeling.

Orphan designation reflects unmet need in RP rather than evidence of efficacy, while offering development incentives and ...

Oryon Cell Therapies ("Oryon"), a clinical-stage biotechnology company focused on developing autologous neuron replacement medicines for Parkinson's disease and other neurodegenerative disorders, ...

Oryon Cell Therapies (“Oryon”), a clinical-stage biotechnology company focused on developing autologous neuron replacement ...